Everything below concerns TB-500. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-24. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Multi-walled nanotubes (MWNTs) consist of multiple rolled layers (concentric tubes) of graphene. There are two models that can be used to describe the structures of multi-walled nanotubes. In the Russian Doll model, sheets of graphite are arranged in concentric cylinders, e.g., a (0,8) single-walled nanotube (SWNT) within a larger (0,17) single-walled nanotube. In the Parchment model, a single sheet of graphite is rolled in around itself, resembling a scroll of parchment or a rolled newspaper. The interlayer distance in multi-walled nanotubes is close to the distance between graphene layers in graphite, approximately 3.4 Å. The Russian Doll structure is observed more commonly. Its individual shells can be described as SWNTs, which can be metallic or semiconducting. Because of statistical probability and restrictions on the relative diameters of the individual tubes, one of the shells, and thus the whole MWNT, is usually a zero-gap metal. Double-walled carbon nanotubes (DWNTs) form a special class of nanotubes because their morphology and properties are similar to those of SWNTs but they are more resistant to attacks by chemicals. This is especially important when it is necessary to graft chemical functions to the surface of the nanotubes (functionalization) to add properties to the CNT. Covalent functionalization of SWNTs will break some C=C double bonds, leaving "holes" in the structure on the nanotube and thus modifying both its mechanical and electrical properties. In the case of DWNTs, only the outer wall is modified.
=== Amino acid enrichment for certain functional categories of LCRs === A bioinformatics analysis of prokaryotic LCRs identified 5 types of amino acid enrichment, for certain functional categories of LCRs:
Meyer even criticized Hutchinson publicly, prompting a meeting between the three men and team owner August Busch Jr., in which Hutchinson appealed to the owner to "Let me alone to do my job." "That thing with Mizell in Brooklyn, I just wanted to get him over a hump," Hutchinson later explained. Through July 27, Mizell had a 5.32 ERA, but his control started to improve in the middle of the year. Called on for a start on July 29, he held the Pirates to two hits in a 4–0 shutout victory. Thereafter, most of his appearances would be starts. With the second-place Cardinals trailing the NL-leading Milwaukee Braves on August 18, Mizell threw a four-hit shutout, helping the Cardinals sweep a doubleheader and remain in the pennant race. His ERA after July 27 was 2.54. In 33 games (21 starts), he had an 8–10 record, a 3.74 ERA, 87 strikeouts, and 51 walks in 149+1⁄3 innings. Over the 1957–58 offseason, Mizell practiced throwing with a steel ball. He arrived early to 1958 spring training, claiming to have lost 12 pounds from the previous spring. He had a 3–6 record entering June 21, but from that date through July 12, he won four straight games. On June 25, though he walked five batters, he allowed just three hits and one unearned run in a 3–1 victory over the Pirates. Then, on July 12, he threw a shutout in a 2–0 win over the Pirates. He had a pitching duel against Joe Nuxhall of Cincinnati in the first game of a doubleheader on September 1; Mizell prevailed 1–0, setting an NL record for most walks in a shutout with nine.
small conditional RNA (scRNA) A class of small RNA molecules engineered so as to change conformation conditionally in response to cognate molecular inputs, often with the goal of controlling signal transduction pathways in vitro or in vivo.
Sources: en.wikipedia.org
=== Amino acid enrichment for certain functional categories of LCRs === A bioinformatics analysis of prokaryotic LCRs identified 5 types of amino acid enrichment, for certain functional categories of LCRs:
=== Single particles === Single particle inductively coupled plasma mass spectrometry (SP-ICP-MS) was designed for particle suspensions in 2000 by Claude Degueldre. He first tested this new methodology at the Forel Institute of the University of Geneva and presented this approach at the 'Colloid 2oo2' symposium during the spring 2002 meeting of the EMRS, and in the proceedings in 2003. This study presents the theory of SP ICP-MS and the results of tests carried out on clay particles (montmorillonite) as well as other suspensions of colloids. This method was then tested on thorium dioxide nanoparticles, zirconium dioxide and gold nanoparticles and uranium dioxide nano- and micro-particles.
== Research == Sarkar discovered copper-histidine in human blood. He invented the treatment of Menkes disease by copper-histidine. He discovered the amino terminal Cu (II)- and Ni (II)- binding (ATCUN) motif of proteins. This motif has been used to cleave DNA, applied as a paramagnetic probe, and used to kill Ehrlich cells. His laboratory identified and characterized the six copper-binding sites of copper-ATPase that is defective in Wilson's disease. He pioneered the development of metalloproteomics, a subdiscipline of proteomics that attempts to identify and characterize all metal-associated proteins in a well-defined system. He also contributed to global health research in Bangladesh, India, Nepal, and Myanmar, where tens of thousands of people are exposed to naturally occurring arsenic and other toxic metals in drinking water from underground wells. Sarkar is considered a pioneer in establishing inorganic biochemistry through his research in the early 1960s. He organized the first international meeting of Biological Inorganic Chemistry in the boardroom of the Hospital for Sick Children in 1972. This initiative was followed by the 56th Nobel Symposium in Inorganic Biochemistry held in Sweden under the auspices of the Nobel Foundation in 1982, where Sarkar was an invited speaker. He has published extensively in scientific journals, organized many series of international symposia on metals and genetics, and edited several books on metals in biology, genetics, and environment.
Sources: en.wikipedia.org
The firm has served as the official energy drink sponsor of multiple X Games contests, including the 2017 summer games in Minneapolis and the 2017 winter games in Aspen. Among the athletes on their team are skateboarders Nyjah Huston, Ishod Wair and Chris Cole, three-time gold-winning skier David Wise, Olympic freestyle skier Gus Kenworthy and Olympic gold medalist snowboarder Iouri Podladtchikov.
In the mid-1960s James R. Rice (then at Brown University) and G. P. Cherepanov independently developed a new toughness measure to describe the case where there is sufficient crack-tip deformation that the part no longer obeys the linear-elastic approximation. Rice's analysis, which assumes non-linear elastic (or monotonic deformation theory plastic) deformation ahead of the crack tip, is designated the J-integral. This analysis is limited to situations where plastic deformation at the crack tip does not extend to the furthest edge of the loaded part. It also demands that the assumed non-linear elastic behavior of the material is a reasonable approximation in shape and magnitude to the real material's load response. The elastic-plastic failure parameter is designated JIc and is conventionally converted to KIc using the equation below. Also note that the J integral approach reduces to the Griffith theory for linear-elastic behavior. The mathematical definition of J-integral is as follows:
=== H: Diseases of the eye, adnexa, ear, and mastoid process === (H04.6) Lacrimal fistula (H05.81) Carotid cavernous fistula (H70.1) Mastoid fistula Craniosinus fistula: between the intracranial space and a paranasal sinus (H83.1) Labyrinthine fistula Perilymph fistula: tear between the membranes between the middle and inner ears Preauricular fistula Preauricular fistula: usually on the top of the cristae helicis of the ears
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.